Generic Name
Clopidogrel Bisulphate
Composition
Clopidogrel Bisulphate 75 mg
Dosage Type
Tablet
Pack Size
10x10
Strength
MRP
Rs. 11
Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease.
Acute Coronary Syndrome
In patients who need an antiplatelet effect within hours, initiate Clopidogrel with a single 300 mg oral loading dose and then continue at 75 mg once daily. Initiating Clopidogrel without a loading dose will delay establishment of an antiplatelet effect by several days [see Clinical Pharmacology and Clinical Studies.
Recent MI, Recent Stroke, or Established Peripheral Arterial Disease
75 mg once daily orally without a loading dose [see Clinical Pharmacology and Clinical Studies].
Diminished Antiplatelet Activity in Patients with Impaired CYP2C19 Function
Clopidogrel is a prodrug. Inhibition of platelet aggregation by Clopidogrel is achieved through an active metabolite. The metabolism of Clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 .
General Risk of Bleeding
P2Y12 inhibitors (thienopyridines), including Clopidogrel, increase the risk of bleeding.
Discontinuation of Clopidogrel Tablets
Discontinuation of Clopidogrel increases the risk of cardiovascular events. If Clopidogrel must be temporarily discontinued (e.g., to treat bleeding or for surgery with a major risk of bleeding), restart it as soon as possible.
Thrombotic Thrombocytopenic Purpura (TTP)
TTP, sometimes fatal, has been reported following use of Clopidogrel, sometimes after a short exposure (<2 weeks). TTP is a serious condition that requires urgent treatment including plasmapheresis (plasma exchange).
Store at room temperature.
CLOPIREL: 10×10’s
